Key points are not available for this paper at this time.
In endovascular stroke therapy, additional treatment with the glycoprotein-IIb/IIIa inhibitor tirofiban is associated with increased risk of fatal intracerebral hemorrhage and poor outcome.
Kellert et al. (Wed,) studied this question.